To enhance the affordability of essential medicines, the National Pharmaceutical Pricing Authority (NPPA) has fixed the Maximum Retail Prices (MRPs) for 30 drug formulations. This decision, announced on May 27, 2026, aims to ensure that commonly used medications remain accessible to the public. Among the medicines affected are Vitamin D3 Oral Solution, Calcium, Methylcobalamin, and various heart-related medications. The NPPA has set the retail price for a tablet containing Vitamin D3, Calcium, Methylcobalamin, Pyridoxal-5 Phosphate, and L-Methylfolate Calcium at ₹19.78. Additionally, Atorvastatin and Fenofibrate Tablets, which are essential for cholesterol management, will now cost ₹18.46 per tablet. The NPPA emphasizes that these price caps will protect consumers from unreasonable price variations and promote transparency in the pharmaceutical market. Manufacturers and marketing companies are mandated to sell these medicines at the established rates, providing patients with relief through fair pricing across the country.